MAPS, a mission-driven organization that works on developing safe and effective medicines, is funding their MDMA clinical trials efficiently with a total budget of around 65 million. They have a team of passionate experts and they have already raised 35 million, $30 million more from Capstone, and profits are reinvested in the mission for further research.